New Advances in Immunotherapy for Non-small Cell Lung Cancer

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2018 Sep 14

PMID 30210667

Citations 30

Authors

Haifeng Qin

Fang Wang

Hui Liu

Zhen Zeng

Shasha Wang

Xin Pan

Hongjun Gao

Affiliations

Soon will be listed here.

Abstract

Immunotherapy is one of the methods that can change the survival rate of patients with malignant tumors, in addition to surgery therapy, radiotherapy, chemotherapy and targeted therapy. Among various immunotherapy methods, immunoprecipitation inhibitors have been the most effective medications developed in recent years. At present, more in-depth studies have been conducted for two immune checkpoint inhibitor pathways, programmed cell death protein 1 (PD-1)/Programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and a variety of medications for those above mentioned. The present study briefly reviews the results of clinical trials for relevant immune checkpoint inhibitors in lung cancer.

Citing Articles

An integrated analysis of related to malignant properties and immune infiltration of gliomas.

Huang C, Qiu O, Mao C, Hu Z, Qu S Cancer Innov. 2023; 1(3):240-251.

PMID: 38089762 PMC: 10686109. DOI: 10.1002/cai2.29.

Circ_0102231 inactivates the PI3K/AKT signaling pathway by regulating the miR-635/NOVA2 pathway to promote the progression of non-small cell lung cancer.

Liu J, Yu Q, Yang X Thorac Cancer. 2023; 14(35):3453-3464.

PMID: 37864285 PMC: 10719657. DOI: 10.1111/1759-7714.15138.

Neoadjuvant Chemoimmunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable Non-small Cell Lung Cancer.

Chen T, Cao Z, Sun Y, Huang J, Shen S, Jin Y Ann Surg Oncol. 2023; 30(12):7549-7560.

PMID: 37587362 DOI: 10.1245/s10434-023-14123-w.

Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics.

Padinharayil H, Varghese J, John M, Rajanikant G, Wilson C, Al-Yozbaki M Genes Dis. 2023; 10(3):960-989.

PMID: 37396553 PMC: 10308181. DOI: 10.1016/j.gendis.2022.07.023.

Downregulation of circ-YES1 suppresses NSCLC migration and proliferation through the miR-142-3p-HMGB1 axis.

Jin M, Wang Y, Zhou D, Liu W, Han R, Chi Y Respir Res. 2023; 24(1):100.

PMID: 37009887 PMC: 10069124. DOI: 10.1186/s12931-023-02378-6.

References

Huard B, Karlsson L . KIR expression on self-reactive CD8+ T cells is controlled by T-cell receptor engagement. Nature. 2000; 403(6767):325-8. DOI: 10.1038/35002105. View

Monney L, Sabatos C, Gaglia J, Ryu A, Waldner H, Chernova T . Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002; 415(6871):536-41. DOI: 10.1038/415536a. View

Huang C, Workman C, Flies D, Pan X, Marson A, Zhou G . Role of LAG-3 in regulatory T cells. Immunity. 2004; 21(4):503-13. DOI: 10.1016/j.immuni.2004.08.010. View

Keir M, Liang S, Guleria I, Latchman Y, Qipo A, Albacker L . Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006; 203(4):883-95. PMC: 2118286. DOI: 10.1084/jem.20051776. View

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

Blackburn S, Shin H, Nicholas Haining W, Zou T, Workman C, Polley A . Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2008; 10(1):29-37. PMC: 2605166. DOI: 10.1038/ni.1679. View

Francisco L, Sage P, Sharpe A . The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236:219-42. PMC: 2919275. DOI: 10.1111/j.1600-065X.2010.00923.x. View

Qureshi O, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt E . Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011; 332(6029):600-3. PMC: 3198051. DOI: 10.1126/science.1202947. View

Turcotte S, Rosenberg S . Immunotherapy for metastatic solid cancers. Adv Surg. 2011; 45:341-60. PMC: 3578602. DOI: 10.1016/j.yasu.2011.04.003. View

10.

Mellman I, Coukos G, Dranoff G . Cancer immunotherapy comes of age. Nature. 2011; 480(7378):480-9. PMC: 3967235. DOI: 10.1038/nature10673. View

11.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

12.

Okamura T, Fujio K, Sumitomo S, Yamamoto K . Roles of LAG3 and EGR2 in regulatory T cells. Ann Rheum Dis. 2012; 71 Suppl 2:i96-100. DOI: 10.1136/annrheumdis-2011-200588. View

13.

Lynch T, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R . Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; 30(17):2046-54. DOI: 10.1200/JCO.2011.38.4032. View

14.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

15.

Huang Y, Zhu C, Kondo Y, Anderson A, Gandhi A, Russell A . CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2014; 517(7534):386-90. PMC: 4297519. DOI: 10.1038/nature13848. View

16.

Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

17.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

18.

Rizvi N, Mazieres J, Planchard D, Stinchcombe T, Dy G, Antonia S . Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015; 16(3):257-65. PMC: 5726228. DOI: 10.1016/S1470-2045(15)70054-9. View

19.

Joyce J, Fearon D . T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015; 348(6230):74-80. DOI: 10.1126/science.aaa6204. View

20.

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. DOI: 10.1056/NEJMoa1501824. View